PE20070614A1 - Derivados biciclicos como antagonistas de nk1/nk3 en el tratamiento de la esquizofrenia - Google Patents
Derivados biciclicos como antagonistas de nk1/nk3 en el tratamiento de la esquizofreniaInfo
- Publication number
- PE20070614A1 PE20070614A1 PE2006001077A PE2006001077A PE20070614A1 PE 20070614 A1 PE20070614 A1 PE 20070614A1 PE 2006001077 A PE2006001077 A PE 2006001077A PE 2006001077 A PE2006001077 A PE 2006001077A PE 20070614 A1 PE20070614 A1 PE 20070614A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- alcoxy
- halogen
- schizophrenia
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0518472A GB0518472D0 (en) | 2005-09-09 | 2005-09-09 | Novel compounds |
| GB0611153A GB0611153D0 (en) | 2006-06-06 | 2006-06-06 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070614A1 true PE20070614A1 (es) | 2007-08-02 |
Family
ID=37546936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001077A PE20070614A1 (es) | 2005-09-09 | 2006-09-07 | Derivados biciclicos como antagonistas de nk1/nk3 en el tratamiento de la esquizofrenia |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US7683056B2 (enExample) |
| EP (2) | EP1928886B1 (enExample) |
| JP (1) | JP5121716B2 (enExample) |
| KR (1) | KR101292348B1 (enExample) |
| CN (1) | CN101305011B (enExample) |
| AR (1) | AR058805A1 (enExample) |
| AT (1) | ATE505472T1 (enExample) |
| AU (1) | AU2006289281B2 (enExample) |
| BR (1) | BRPI0615787B8 (enExample) |
| CA (1) | CA2621564C (enExample) |
| CR (1) | CR9847A (enExample) |
| CY (1) | CY1111907T1 (enExample) |
| DE (1) | DE602006021323D1 (enExample) |
| DK (1) | DK1928886T3 (enExample) |
| EA (1) | EA013909B1 (enExample) |
| HR (1) | HRP20110457T1 (enExample) |
| IL (1) | IL189578A (enExample) |
| JO (1) | JO2722B1 (enExample) |
| MA (1) | MA29780B1 (enExample) |
| MY (1) | MY145713A (enExample) |
| NO (1) | NO340921B1 (enExample) |
| NZ (1) | NZ565983A (enExample) |
| PE (1) | PE20070614A1 (enExample) |
| PL (1) | PL1928886T3 (enExample) |
| PT (1) | PT1928886E (enExample) |
| SI (1) | SI1928886T1 (enExample) |
| TW (1) | TWI378101B (enExample) |
| WO (1) | WO2007028654A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007039123A2 (en) * | 2005-09-22 | 2007-04-12 | Smithkline Beecham Corporation | Combination therapy comprising an nk-3 antagonist and an antipsychotic agent |
| EP1943216B1 (en) * | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
| TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| PT2404919E (pt) | 2005-11-08 | 2013-10-22 | Vertex Pharma | Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| US8093268B2 (en) | 2007-01-24 | 2012-01-10 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) |
| EA015952B1 (ru) | 2007-05-03 | 2011-12-30 | Пфайзер Лимитед | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов |
| EP2164840A2 (en) | 2007-05-09 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
| CA2989620C (en) | 2007-12-07 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| HUE049642T2 (hu) | 2007-12-07 | 2020-09-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái |
| EP2098526B1 (en) * | 2008-02-22 | 2014-01-15 | Neurotune AG | Nitrogen-containing bicyclic compounds active on chronic pain conditions |
| CA2716109C (en) | 2008-02-28 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
| FR2928150A1 (fr) | 2008-02-29 | 2009-09-04 | Vetoquinol Sa Sa | Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens |
| WO2009119528A1 (ja) * | 2008-03-24 | 2009-10-01 | 武田薬品工業株式会社 | 複素環化合物 |
| GB0808747D0 (en) * | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| EP2145891A1 (en) | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
| GB0814340D0 (en) * | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
| UY32826A (es) | 2009-08-04 | 2011-02-28 | Takeda Pharmaceutical | Compuestos heterocíclicos |
| ES2440938T3 (es) * | 2009-08-27 | 2014-01-31 | Nerre Therapeutics Limited | Formas anhidrato de un derivado de piridina |
| WO2011054773A1 (en) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Novel lactam compounds |
| ES2900353T3 (es) | 2010-04-07 | 2022-03-16 | Vertex Pharma | Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas |
| ES2529233T3 (es) | 2010-07-09 | 2015-02-18 | Convergence Pharmaceuticals Limited | Compuestos tetrazol como bloqueadores de canales de calcio |
| US8648118B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
| CN102617503B (zh) * | 2011-03-03 | 2014-05-07 | 上海常丰生物医药科技有限公司 | (s)-3-吗啉基羧酸的合成方法 |
| UY34349A (es) | 2011-09-29 | 2013-04-05 | Abb Vie Inc | OCTAHIDROPIRROLO[1,2-a]PIRAZINA SULFONAMIDAS SUSTITUIDAS COMO BLOQUEADORES DE CANALES DE CALCIO |
| WO2013049164A1 (en) * | 2011-09-29 | 2013-04-04 | Abbvie Inc. | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS |
| NZ727015A (en) | 2012-01-25 | 2017-12-22 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| AU2013359533A1 (en) | 2012-12-12 | 2015-05-28 | Abbvie, Inc. | Diazepine derivatives useful as calcium channel blockers in the treatment of pain |
| CA2930008A1 (en) | 2013-11-08 | 2015-05-14 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
| CA2930199C (en) | 2013-11-12 | 2022-10-25 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| JP6609253B2 (ja) * | 2014-08-06 | 2019-11-20 | キッセイ薬品工業株式会社 | シアノチオフェン誘導体 |
| HUE055423T2 (hu) | 2014-11-18 | 2021-11-29 | Vertex Pharma | Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére |
| WO2016102967A1 (en) | 2014-12-23 | 2016-06-30 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| AU2016264034B2 (en) * | 2015-05-18 | 2020-03-05 | KaNDy Therapeutics Limited | Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases |
| EP3691634A4 (en) | 2017-10-05 | 2021-03-31 | Biogen Inc. | PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES |
| EA202092131A1 (ru) * | 2018-03-14 | 2020-11-27 | Кэнди Терапьютикс Лимитед | Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3 |
| US11583538B2 (en) | 2019-04-08 | 2023-02-21 | Venenum Biodesign, LLC | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors |
| EP4058433A1 (en) * | 2019-11-15 | 2022-09-21 | KaNDy Therapeutics Limited | New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814 |
| WO2021261969A1 (ko) * | 2020-06-26 | 2021-12-30 | 홀로스메딕 주식회사 | 신규한 화합물의 제조방법 |
| KR102682775B1 (ko) * | 2020-06-26 | 2024-07-08 | 홀로스메딕 주식회사 | 신규한 화합물의 제조방법 |
| WO2022075974A1 (en) * | 2020-10-06 | 2022-04-14 | Venenum Biodesign, LLC | Cyclic trex1 inhibitors |
| JP2024514533A (ja) * | 2021-04-05 | 2024-04-02 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 神経伝達に対する鏡像異性体選択的作用 |
| EP4431512A1 (en) | 2023-03-16 | 2024-09-18 | Bayer Consumer Care AG | Novel dual nk-1/nk-3 receptor antagonists |
| WO2025242585A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
| WO2025242584A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | A stable soft gelatin capsule formulation for elinzanetant |
| TW202604529A (zh) | 2024-06-18 | 2026-02-01 | 瑞士商拜耳保健消費品股份有限公司 | 用於製造依林奈坦(elinzanetant)前驅物之改良方法 |
| CN122427188A (zh) * | 2025-01-21 | 2026-07-21 | 安礼特（上海）医药科技有限公司 | 依林奈坦及其中间体的制备方法 |
| CN122427189A (zh) * | 2025-01-21 | 2026-07-21 | 安礼特（上海）医药科技有限公司 | 依林奈坦中间体及依林奈坦的制备方法 |
| WO2026156530A1 (en) | 2025-01-22 | 2026-07-30 | Bayer Consumer Care Ag | New chemical process for the production of 4- (4-fluoro-2-methyl-phenyl) -5-nitro-1h-pyridin-2-one, a key intermediate of elinzanetant |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921855A (en) | 1987-06-22 | 1990-05-01 | Fujisawa Pharmaceutical Co., Ltd. | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same |
| US5166203A (en) | 1990-08-30 | 1992-11-24 | Kanebo, Ltd. | Quinolinecarboxylic acid derivatives, antibacterial agent containing the same |
| EP1486498A1 (en) | 1998-11-23 | 2004-12-15 | Pfizer Products Inc. | Process and intermediates for growth hormone secretagogues |
| EP1035115B1 (en) | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| GT200000203A (es) | 1999-12-01 | 2002-05-24 | Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas. | |
| TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
| ES2291891T3 (es) | 2003-07-03 | 2008-03-01 | F. Hoffmann-La Roche Ag | Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia. |
-
2006
- 2006-09-07 DK DK06777183.2T patent/DK1928886T3/da active
- 2006-09-07 PE PE2006001077A patent/PE20070614A1/es not_active Application Discontinuation
- 2006-09-07 HR HR20110457T patent/HRP20110457T1/hr unknown
- 2006-09-07 SI SI200631047T patent/SI1928886T1/sl unknown
- 2006-09-07 DE DE602006021323T patent/DE602006021323D1/de active Active
- 2006-09-07 AR ARP060103894A patent/AR058805A1/es active IP Right Grant
- 2006-09-07 NZ NZ565983A patent/NZ565983A/en not_active IP Right Cessation
- 2006-09-07 CA CA2621564A patent/CA2621564C/en active Active
- 2006-09-07 WO PCT/EP2006/008845 patent/WO2007028654A1/en not_active Ceased
- 2006-09-07 PL PL06777183T patent/PL1928886T3/pl unknown
- 2006-09-07 MY MYPI20064110A patent/MY145713A/en unknown
- 2006-09-07 US US12/065,923 patent/US7683056B2/en active Active
- 2006-09-07 JO JO2006301A patent/JO2722B1/en active
- 2006-09-07 CN CN2006800418603A patent/CN101305011B/zh active Active
- 2006-09-07 EP EP06777183A patent/EP1928886B1/en active Active
- 2006-09-07 AT AT06777183T patent/ATE505472T1/de active
- 2006-09-07 EP EP10190918A patent/EP2336136A1/en not_active Withdrawn
- 2006-09-07 AU AU2006289281A patent/AU2006289281B2/en active Active
- 2006-09-07 TW TW095132989A patent/TWI378101B/zh active
- 2006-09-07 PT PT06777183T patent/PT1928886E/pt unknown
- 2006-09-07 BR BRPI0615787A patent/BRPI0615787B8/pt active IP Right Grant
- 2006-09-07 EA EA200800784A patent/EA013909B1/ru unknown
- 2006-09-07 JP JP2008529564A patent/JP5121716B2/ja active Active
- 2006-09-07 KR KR1020087008441A patent/KR101292348B1/ko active Active
-
2008
- 2008-02-18 IL IL189578A patent/IL189578A/en active IP Right Grant
- 2008-03-17 MA MA30749A patent/MA29780B1/fr unknown
- 2008-03-28 CR CR9847A patent/CR9847A/es not_active Application Discontinuation
- 2008-04-07 NO NO20081728A patent/NO340921B1/no unknown
-
2009
- 2009-12-14 US US12/636,849 patent/US7919491B2/en active Active
-
2011
- 2011-02-23 US US13/032,740 patent/US8097618B2/en active Active
- 2011-07-04 CY CY20111100641T patent/CY1111907T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110457T1 (hr) | Derivati piridina i njihova upotreba u liječenju psihotičnih poremećaja | |
| ME02409B (me) | Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja | |
| PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
| PE20050694A1 (es) | Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina | |
| PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
| PE20081612A1 (es) | Analogos de las pterinas | |
| RU2350616C2 (ru) | Производные пиразоло- и имидазопиримидина | |
| PE20120126A1 (es) | Nuevas bencenosulfonamidas como bloqueadores de canales de calcio | |
| PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
| PE20011287A1 (es) | Derivados de imidazopirimidina y derivados de triazolopirimidina | |
| JP2013509438A5 (enExample) | ||
| PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
| PE20140623A1 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
| PE20210856A1 (es) | Derivados sustituidos de la carboxamida dihidropirazolo pirazina | |
| PE20121613A1 (es) | Derivados de quinolina amida como moduladores alostericos positivos de receptores m1 | |
| PE20090441A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA | |
| ATE493407T1 (de) | 3-(heteroaryloxy)-2-alkyl-1- azabicycloalkylderivate als alpha.7-nachr- liganden zur behandlung von zns-erkrankungen | |
| PE20120505A1 (es) | Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a | |
| PE20090288A1 (es) | Derivados de quinoxalina como inhibidores de la pi3 quinasa | |
| PE20091819A1 (es) | DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA | |
| PE20191156A1 (es) | Nuevos derivados de isoxazolil eter como pam de gabaa alfa5 | |
| PE20070978A1 (es) | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) | |
| CY1109890T1 (el) | ΠΑΡΑΓΩΓΑ 8-ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ-6,7,8,9- ΤΕΤΡΑΫΔΡΟΠΥΡΙΜΙΔΟ[1,2-α] ΠΥΡΙΜΙΔΙΝ-4-ΟΝΗΣ | |
| PE20110303A1 (es) | Derivados de heteroaril acetamidas como activadores de glucoquinasa | |
| PE20110122A1 (es) | COMPUESTOS DERIVADOS DE 9H-PIRROLO[2,3-b:5,4-c]DIPIRIDIN-6-(PIRIDIN-3-IL) COMO INHIBIDORES DE LAS CINASA Pim |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |